Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn

Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma